| PROFIT AND LOSS | H1 2019 | H1 2018 | Growth as reported | Growth at CER* | |||||
| DKK million | |||||||||
| Net sales | 59,327 | 54,337 | 9 | % | 5 | % | |||
| Operating profit | 27,691 | 24,652 | 12 | % | 6 | % | |||
| Net profit | 20,040 | 21,094 | (5 | %) | N/A | ||||
| Diluted earnings per share (in DKK) | 8.39 | 8.66 | (3 | %) | N/A | ||||
* CER: Constant exchange rates (average 2018)
Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the sales growth in the first half of 2019, which is driven by all regions in International Operations. The launch of Ozempic® is expanding the GLP-1 market, and we are encouraged by the positive market reception in both North America and Europe. With the initiation of four major late-stage clinical trials, we continue to investigate the clinical benefits of semaglutide across multiple indications. The solid financial performance in the first half of 2019 has enabled us to raise our outlook for the full-year”.
On 9 August 2019 at 13.00 CEST, corresponding to 7.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
Further information
| Media: | ||
| Mette Kruse Danielsen | +45 4442 3883 | mkd@novonordisk.com |
| Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
| Kristoffer Due Berg US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 46 /2019
Attachment